GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C GeneDx (Nasdaq: WGS) and Zevra Therapeutics announced a Sponsored Genetic Testing Program to expand access to GeneDx’s ExomeDx test for U.S. patients with suspected Niemann-Pick disease type C (NPC). Eligible patients may receive testing at no charge, with results available in as little as three weeks.De-identified data from the program will be added to GeneDx Infinity™, aiming to improve NPC diagnosis speed and support clinical decision-making as new therapies emerge. Zevra will provide financial support for the program.

#WGS #ZVRA GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

www.stocktitan.net/news/WGS/gene-dx-to-laun...

Zevra Reports Fourth Quarter and Full Year 2025 Financial Results Zevra (NASDAQ: ZVRA) reported Q4 revenue of $34.1M (Q4 growth 31% QoQ) and FY2025 net revenue of $106.5M, driven by MIPLYFFA net revenue $87.4M. FY2025 net income was $83.2M ($1.40 basic, $1.35 diluted). Cash and securities totaled $238.9M at year-end.Regulatory progress: EMA MAA under review; U.S. EAP enrolled 113 patients; Phase 3 DiSCOVER enrollment ongoing (52 patients).

#ZVRA Zevra Reports Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/ZVRA/zevra-reports-...

Zevra to detail 2025 results in March 9 earnings call Fourth-quarter and 2025 results from Zevra will be released March 9 after market close, followed by a 4:30 p.m. ET call and 90-day webcast replay.

#ZVRA Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call

www.stocktitan.net/news/ZVRA/zevra-therapeu...

Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC) Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has executed an exclusive expanded access

#ZVRA Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC)

www.stocktitan.net/news/ZVRA/zevra-therapeu...

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#PLTR, #WULF, #QBTS, #TMC, #ZVRA

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CRDF, #CIB, #ZVRA, #NKLR, #CXW

#OptionFlow #OptionsTrading #Trading

Zevra Therapeutics, Inc. Announces CFO Transition Zevra Therapeutics (NasdaqGS: ZVRA) announced that Chief Financial Officer and Treasurer R. LaDuane Clifton will step down effective December 31, 2025 to pursue other professional opportunities. Clifton has served since 2015, and company leadership said he helped guide Zevra from development stage to a commercial-stage rare disease company and left a strong financial foundation.The company has initiated a search for a new chief financial officer. No replacement has been named and no financial metrics or guidance changes were disclosed.

#ZVRA Zevra Therapeutics, Inc. Announces CFO Transition

www.stocktitan.net/news/ZVRA/zevra-therapeu...

Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call Zevra Therapeutics (NASDAQ: ZVRA) will report Q3 2025 corporate and financial results on Wednesday, November 5, 2025 after market close. The company will host a conference call and audio webcast the same day at 4:30 p.m. ET.A webcast link and replay (available for 90 days) are accessible on the Events & Presentations page in the Investor Relations section at investors.zevra.com. Telephone dial-in: US: (800) 579-2543; International: +1 (785) 424-1789. Conference ID: ZVRAQ325. Replay begins at ~5:30 p.m. ET on November 5, 2025.

#ZVRA Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call

www.stocktitan.net/news/ZVRA/zevra-therapeu...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#UROY, #VERI, #ZVRA, #FUBO, #BTDR

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #UROY 37.8x
2. #VERI 23.9x
3. #ZVRA 16.6x
4. #TE 6.4x
5. #FUBO 5.8x

#OptionFlow #OptionsTrading #Trading

#ZVRA 10C for Oct. 10 is a bit of a wall, but if it can break out there is no resistance until 12.

#ZVRA likely sold 5P for Dec 2026 into 9-14C Spread for Jan. A couple insider buys lately, but nothing spectacular.

Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM) Zevra Therapeutics (NasdaqGS: ZVRA) announced that four posters on MIPLYFFA® (arimoclomol) will be presented at the International Congress of Inborn Errors of Metabolism (ICIEM) in Kyoto, Japan, September 2-6, 2025. MIPLYFFA, approved in the U.S. for treating Niemann-Pick disease type C (NPC), will be featured in presentations including a Best Poster award winner highlighting its mechanism of action.The presentations will showcase new data from a multi-center pediatric substudy in patients under two years old and a new prespecified efficacy analysis of patients on routine clinical care with miglustat who switched from placebo to MIPLYFFA. The drug has demonstrated long-term clinical outcomes across more than 270 NPC patients worldwide through various clinical trials and programs, representing the most extensive clinical development program in NPC to date.

#ZVRA Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)

www.stocktitan.net/news/ZVRA/zevra-therapeu...

Zevra Revenue Jumps 486 Percent in Q2 | The Motley Fool

#ZVRA #885ccd96-bfb2-4bf1-9abd-2b6fea1321f5 #data-news

Origin | Interest | Match

Zevra's Q2 Revenue Surges to $25.9M as Rare Disease Drug Launch Gains Momentum Rare disease specialist reports strong MIPLYFFA sales, bolsters cash position to $217.7M with PRV sale. European expansion underway with new regulatory submission. See results.

#ZVRA Zevra Reports Second Quarter 2025 Financial Results and Corporate Update

www.stocktitan.net/news/ZVRA/zevra-reports-...

Rare Disease Leader Zevra Therapeutics Sets Q2 2025 Earnings Call - Key Details Inside Access Zevra's Q2 2025 earnings webcast on August 12 at 4:30 PM ET. Rare disease treatment updates and financial performance insights await. Join now.

#ZVRA Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call

www.stocktitan.net/news/ZVRA/zevra-therapeu...

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C Zevra Therapeutics (NASDAQ:ZVRA) has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for arimoclomol, targeting the treatment of Niemann-Pick Disease Type C (NPC). The drug, marketed as MIPLYFFA® in the U.S., is the only treatment directly addressing NPC's underlying pathology by enhancing lipid clearance through increased gene expression.The submission is supported by extensive clinical data from over 270 NPC patients, including Phase 2/3 trials, Open-Label Extension study, Expanded Access Programs, and a pediatric sub-study, representing 5-7 years of patient experience. Currently, 89 European patients are enrolled in the company's Expanded Access Program as of Q2.

#ZVRA Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

www.stocktitan.net/news/ZVRA/zevra-therapeu...

Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG) Zevra Therapeutics (NASDAQ:ZVRA) announced the presentation of four posters at the 42nd Annual Meeting of the Southeastern Regional Genetics Group (SERGG) in Asheville, North Carolina. Three posters focus on MIPLYFFA® (arimoclomol) for Niemann-Pick disease type C (NPC) and one on OLPRUVA® (sodium phenylbutyrate) for urea cycle disorders.The MIPLYFFA presentations highlight long-term efficacy data showing disease stabilization for up to 5 years in treated patients, real-world outcomes from the U.S. Expanded Access Program, and insights into the drug's mechanism of action. The OLPRUVA presentation demonstrates successful administration through gastrostomy tubes, expanding treatment options for UCD patients.

#ZVRA Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)

www.stocktitan.net/news/ZVRA/zevra-therapeu...

Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference Zevra Therapeutics (NasdaqGS: ZVRA) announced that its FDA-approved treatment MIPLYFFA® (arimoclomol) will be featured in three presentations at the National Niemann Pick Disease Foundation Conference in July 2025. MIPLYFFA is the first FDA-approved treatment for Niemann-Pick disease type C (NPC), indicated for use with miglustat in patients 2 years and older.The presentations include clinical data showing that MIPLYFFA, combined with miglustat, halted disease progression at 12 months in pivotal trials. Long-term data from a 48-month open-label extension confirmed the treatment's effectiveness and safety profile. Additional research demonstrated MIPLYFFA's mechanism of action through upregulation of CLEAR genes and improvement of lysosomal function.

#ZVRA Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference

www.stocktitan.net/news/ZVRA/zevra-therapeu...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with improving money flow, Mon Jul 7th - #ZVRA #ZJK #XHG #VIGL #TRS #MDIA #LNSR #KRMD #BTCS #ALLR #OCFT #MUX #MED #AMPX - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Zevra Earnings: Rare Disease Treatments Drive 500% Revenue Growth as $150M Cash Infusion Fuels Expansion Q1 revenue soars on MIPLYFFA success while $150M PRV sale strengthens balance sheet. See how Zevra's rare disease portfolio is transforming financial outlook. Get details.

#ZVRA Zevra Reports First Quarter 2025 Financial Results and Corporate Update

www.stocktitan.net/news/ZVRA/zevra-reports-...

Zevra Therapeutics Sets Q1 2025 Earnings Date: Key Details for Rare Disease Portfolio Update Get access details for Zevra's Q1 2025 earnings call on May 13. Rare disease therapy updates and financial performance insights await. Join the discussion.

#ZVRA Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call

www.stocktitan.net/news/ZVRA/zevra-therapeu...

Proxy Fight Erupts at Zevra: Former CEO Challenges $150M Cash-Rich Biotech Amid record revenues and $150M cash infusion, Zevra's board fights proxy contest from ex-CEO. Two board seats at stake as company defends strategic direction.

#ZVRA Zevra Therapeutics Files Preliminary Proxy

www.stocktitan.net/news/ZVRA/zevra-therapeu...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with improving money flow, Tue Mar 11th - #UFCS #ZVRA #RGR #TSVT #SLRN #RANI #QURE #PFC #MMLP #INBX #CRVO #BLTE - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Zevra Earnings: Q4 Revenue Surges to $12M as MIPLYFFA Launch Gains Traction Zevra reports Q4 momentum with MIPLYFFA launch success, extends cash runway to 2029 through $150M PRV sale. Strong commercial progress despite increased R&D investment.

#ZVRA Zevra Reports Full Year 2024 and Fourth Quarter Financial Results

www.stocktitan.net/news/ZVRA/zevra-reports-...

How Will Zevra Use Its Massive $150M Windfall? Non-Dilutive Funding Fuels Rare Disease Strategy Non-dilutive capital to fund MIPLYFFA and OLPRUVA commercial launches while advancing rare disease pipeline development without shareholder dilution.

#ZVRA Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

www.stocktitan.net/news/ZVRA/zevra-therapeu...

Zevra Therapeutics Secures Coveted Spot in Nasdaq Biotechnology Index Following Transformative Year Zevra Therapeutics achieves significant milestone with inclusion in the prestigious Nasdaq Biotechnology Index, marking enhanced visibility for institutional investors.

#ZVRA Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024

www.stocktitan.net/news/ZVRA/zevra-therapeu...

Zevra Therapeutics Overhauls Operations, Shifts Focus to Late-Stage Rare Disease Pipeline | ZVRA Stock News Zevra streamlines operations with major organizational changes, consolidating development under CMO as it transforms into a rare disease-focused therapeutics company.

#ZVRA Zevra Therapeutics Announces Organizational Changes

#StockMarket #stocks #investing

www.stocktitan.net/news/ZVRA/zevra-therapeu...

#ZVRA Zevra Therapeutics to Participate at Upcoming Investor Conferences

www.stocktitan.net/news/ZVRA/zevra-therapeu...